Here are the 10-K annual reports from Aktis Oncology, Inc. (AKTS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow AKTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AKTS filings page.
Aktis Oncology is a clinical-stage company developing targeted radiopharmaceuticals built on a proprietary miniprotein radioconjugate platform designed to deliver alpha-emitting radioisotopes precisely to solid tumors while clearing quickly from normal tissue.
Its lead candidate, [225Ac]Ac-AKY-1189, targets Nectin-4–expressing tumors, including urothelial cancer, breast and lung cancers. A Phase 1b trial is under way in the United States, with preliminary dose-escalation data expected in the first quarter of 2027, and the program has FDA Fast Track Designation for locally advanced or metastatic urothelial cancer after prior systemic therapies.
The second program, [225Ac]Ac-AKY-2519, targets B7-H3–expressing tumors such as prostate and lung cancers and is moving into a Phase 1b trial after FDA clearance of related INDs. Aktis is also building an internal cGMP radiopharmaceutical facility anticipated to be operational in the second half of 2026 and has a discovery collaboration with Eli Lilly that included a $60.0 million upfront payment and eligibility for up to $1.2 billion in milestones, while retaining full rights to its own pipeline. The company highlights substantial scientific, clinical, regulatory, funding and manufacturing risks typical for an early-stage oncology platform with no approved products.